217 related articles for article (PubMed ID: 36544653)
1. The efficacy of oxaliplatin, surufatinib, and camrelizumab on neuroendocrine carcinoma: a case report and literature review.
Wang X; Hu S; Su F; Lin J; Duan J; Tan H; Tan H
Ann Transl Med; 2022 Nov; 10(22):1254. PubMed ID: 36544653
[TBL] [Abstract][Full Text] [Related]
2. Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial.
Zhang P; Shi S; Xu J; Chen Z; Song L; Zhang X; Cheng Y; Zhang Y; Ye F; Li Z; Yin F; Ji D; Gao H; Li Y; Chen W; Yang M; Weng D; Wu C; Ma Y; Sheng W; Zhao Y; Yin X; Shen W; Su W; Shi M; Fan S; Tan P; Xu Q; Lu M; Shen L
Eur J Cancer; 2024 Mar; 199():113539. PubMed ID: 38237373
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine Carcinoma of Gall Bladder: A Series of 19 Cases with Review of Literature.
Kamboj M; Gandhi JS; Gupta G; Sharma A; Pasricha S; Mehta A; Chandragouda D; Sinha R
J Gastrointest Cancer; 2015 Dec; 46(4):356-64. PubMed ID: 26208508
[TBL] [Abstract][Full Text] [Related]
4. Salvage camrelizumab plus apatinib for relapsed esophageal neuroendocrine carcinoma after esophagectomy: a case report and review of the literature.
Liu L; Liu Y; Gong L; Zhang M; Wu W
Cancer Biol Ther; 2020 Nov; 21(11):983-989. PubMed ID: 33092443
[TBL] [Abstract][Full Text] [Related]
5. Exploring Real World Outcomes with Nivolumab Plus Ipilimumab in Patients with Metastatic Extra-Pulmonary Neuroendocrine Carcinoma (EP-NEC).
Mohamed A; Vijayvergia N; Kurian M; Liu L; Fu P; Das S
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681675
[No Abstract] [Full Text] [Related]
6. Thymoquinone Plus Immunotherapy in Extra-Pulmonary Neuroendocrine Carcinoma: Case Series for a Novel Combination.
Mohamed A; Azmi AS; Asa SL; Tirumani SH; Mahipal A; Cjakrabarti S; Bajor D; Selfridge JE; Kaseb AO
Curr Oncol; 2022 Nov; 29(11):9018-9030. PubMed ID: 36421360
[TBL] [Abstract][Full Text] [Related]
7. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study.
Xu J; Shen L; Zhou Z; Li J; Bai C; Chi Y; Li Z; Xu N; Li E; Liu T; Bai Y; Yuan Y; Li X; Wang X; Chen J; Ying J; Yu X; Qin S; Yuan X; Zhang T; Deng Y; Xiu D; Cheng Y; Tao M; Jia R; Wang W; Li J; Fan S; Peng M; Su W
Lancet Oncol; 2020 Nov; 21(11):1500-1512. PubMed ID: 32966811
[TBL] [Abstract][Full Text] [Related]
8. Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Peng Z; Wei J; Wang F; Ying J; Deng Y; Gu K; Cheng Y; Yuan X; Xiao J; Tai Y; Wang L; Zou J; Zhang Y; Shen L
Clin Cancer Res; 2021 Jun; 27(11):3069-3078. PubMed ID: 33766817
[TBL] [Abstract][Full Text] [Related]
9. S-1 plus temozolomide as second-line treatment for neuroendocrine carcinoma of the breast: A case report.
Wang X; Shi YF; Duan JH; Wang C; Tan HY
World J Clin Cases; 2021 Aug; 9(24):7146-7153. PubMed ID: 34540971
[TBL] [Abstract][Full Text] [Related]
10. Treatment-related adverse events as predictive biomarkers of efficacy in patients with advanced neuroendocrine tumors treated with surufatinib: results from two phase III studies.
Li J; Cheng Y; Bai C; Xu J; Shen L; Li J; Zhou Z; Li Z; Chi Y; Yu X; Li E; Xu N; Liu T; Lou W; Bai Y; Yuan X; Wang X; Yuan Y; Chen J; Guan S; Fan S; Su W
ESMO Open; 2022 Apr; 7(2):100453. PubMed ID: 35344750
[TBL] [Abstract][Full Text] [Related]
11. A rare case of small cell neuroendocrine carcinoma of gallbladder origin.
Dülger UC; Erdem Ş; Cünük ES; Altıntoprak F
J Surg Case Rep; 2024 Jun; 2024(6):rjae386. PubMed ID: 38832057
[TBL] [Abstract][Full Text] [Related]
12. A case of colorectal large cell neuroendocrine carcinoma accompanied by disseminated peritoneal leiomyomatosis.
Suga K; Ogawa H; Sohda M; Katayama C; Ozawa N; Osone K; Okada T; Shiraishi T; Katoh R; Sano A; Sakai M; Yokobori T; Shirabe K; Saeki H
Surg Case Rep; 2020 Dec; 6(1):316. PubMed ID: 33296060
[TBL] [Abstract][Full Text] [Related]
13. The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma.
Yoon SE; Kim JH; Lee SJ; Lee J; Park SH; Park JO; Lim HY; Kang WK; Park YS; Kim ST
J Cancer; 2019; 10(14):3140-3144. PubMed ID: 31289584
[No Abstract] [Full Text] [Related]
14. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study.
Xu J; Shen L; Bai C; Wang W; Li J; Yu X; Li Z; Li E; Yuan X; Chi Y; Yin Y; Lou W; Xu N; Bai Y; Zhang T; Xiu D; Wang X; Yuan Y; Chen J; Qin S; Jia R; Lu M; Cheng Y; Zhou Z; Li J; He J; Su W
Lancet Oncol; 2020 Nov; 21(11):1489-1499. PubMed ID: 32966810
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of first-line checkpoint inhibitors in combination with chemotherapy in high-grade extrapulmonary metastatic neuroendocrine carcinomas.
Gile JJ; McGarrah PW; Leventakos K; Sonbol MB; Starr JS; Eiring RA; Hobday TJ; Halfdanarson TR
J Neuroendocrinol; 2023 May; 35(5):e13283. PubMed ID: 37229903
[TBL] [Abstract][Full Text] [Related]
16. Comparison of chemotherapeutic treatment outcomes of advanced extrapulmonary neuroendocrine carcinomas and advanced small-cell lung carcinoma.
Terashima T; Morizane C; Hiraoka N; Tsuda H; Tamura T; Shimada Y; Kaneko S; Kushima R; Ueno H; Kondo S; Ikeda M; Okusaka T
Neuroendocrinology; 2012; 96(4):324-32. PubMed ID: 22572060
[TBL] [Abstract][Full Text] [Related]
17. Is the Morphological Subtype of Extra-Pulmonary Neuroendocrine Carcinoma Clinically Relevant?
Frizziero M; Durand A; Taboada RG; Zaninotto E; Luchini C; Chakrabarty B; Hervieu V; Claro LCL; Zhou C; Cingarlini S; Milella M; Walter T; Riechelmann RS; Lamarca A; Hubner RA; Mansoor W; Valle JW; McNamara MG
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439308
[TBL] [Abstract][Full Text] [Related]
18. Transcatheter arterial chemoembolization of apatinib and camrelizumab (SHR1210) against liver metastasis from hepatic neuroendocrine tumor: a case report.
Qi R; Yang W; Zhu S; Mao J; Yang B; Xu A; Fu Q
Front Oncol; 2024; 14():1278340. PubMed ID: 38384807
[TBL] [Abstract][Full Text] [Related]
19. First-line treatment of camrelizumab combined with chemotherapy in advanced gastroenteropancreatic neuroendocrine carcinoma: Study protocol for a prospective, multicenter, phase II study.
Li X; Ma Q; Chang C; Li H; Cao D
Front Oncol; 2022; 12():958905. PubMed ID: 36185252
[TBL] [Abstract][Full Text] [Related]
20. Systematic review and two new cases of primary upper urinary tract neuroendocrine carcinomas.
Nakasato T; Hiramatsu A; Matsui Y; Unoki T; Shimoyama H; Oshinomi K; Morita J; Maeda Y; Naoe M; Fuji K; Ogura H; Homma M; Yamochi T; Takimoto M; Ogawa Y
Cancer Treat Res Commun; 2018; 17():23-30. PubMed ID: 30326420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
